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Abstract
CONTROL OF CELL CYCLE PROGRESSION BY mTOR
By Amrita Chatterjee
Advisor: Professor David A. Foster
Over the past few years it has become apparent that cancer cells require the activation of a
set of intra-cellular signals that promote cell cycle progression and survival. One of the most
common survival signals activated in human cancers is mediated by mTOR –the mammalian
target of rapamycin. mTOR is a critical nutrient and energy sensor in cells that lets the cell know
that there is sufficient material available for a cell to double its mass and divide. mTOR causes
the phosphorylation of downstream targets ribosomal subunit S6 kinase and eukaryotic initiation
factor 4E (eIF4E) binding protein-1 (4E-BP1), which promotes cell cycle progression. mTOR
suppresses the activity of the tumor suppressor Transforming Growth Factor- (TGF-β). TGF-
plays a central role in causing G1 cell cycle arrest. Rapamycin is a highly specific allosteric
inhibitor of mTOR. In the presence of serum, rapamycin activates TGF- signaling and causes
G1 cell cycle arrest. This is one reason why rapamycin is frequently called a “cytostatic drug”.
While conventional low (nM) doses of rapamycin can retard G1 cell cycle progression, our lab
has recently found that high (μM) doses of rapamycin are needed to induce complete G1 cell
cycle arrest. However, it is unclear as to what causes the cells to be sensitive to high dose
rapamycin treatment with regard to G1 cell cycle progression.
Prior studies in lab has shown that rapamycin in absence of serum induces apoptosis. High
dose rapamycin inhibits eIF4E. In this study we revealed that knockdown of eIF4E causes
apoptosis both in the presence and absence of serum. This was unexpected because rapamycin
induces G1 cell cycle arrest in the presence of serum. Upon investigation, we have found that
iv

inactivated S6 kinase prevents the apoptotic effect observed by singular knockdown of eIF4E
and results in G1 cell cycle arrest. This effect is dependent on TGF-β signaling which
contributes to G1 cell cycle arrest. Suppression of S6 kinase phosphorylation alone is
insufficient to cause complete cell cycle arrest, indicating that complete G1 cell cycle arrest is
due to suppression of both S6 kinase and eIF4E. This proves that the cytostatic effect of
rapamycin is suppression of both S6 kinase and eIF4E, while the cytotoxic effects are due
suppression of eIF4E in the absence of S6 kinase-dependent activation of TGF- signals.
This study also shows that nano-molar doses that inhibit S6 kinase were sufficient to
activate TGF- signaling. The high doses of rapamycin used to inhibit eIF4E correlated with
inhibition of Rb phosphorylation. Consistent with these observations, knockdown of both Smad4
(an important player of TGF-β signaling) and Rb reversed the cytostatic effects of rapamycin.
These data indicate that the G1 cell cycle arrest induced by rapamycin is due to the up regulation
of TGF- signaling and down-regulation of Rb phosphorylation via phosphorylation of the
mTORC1 substrates S6 kinase and 4E-BP1 respectively.
Altogether, our findings not only place an importance to the evaluation of the
activity/expression level of S6 kinase and eIF4E as readouts for rapamycin efficacy but also
enhance the current understanding of the cytostatic effects of mTORC1 suppression with
therapeutic implications.
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CHAPTER I:
INTRODUCTION
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1.1THE CELL CYCLE
1.1.1OVERVIEW
Cells reproduce by performing an orderly sequence of events in which it duplicates its
content and then divides in two. This cycle of duplication and division is called the cell cycle.
The cell cycle has the following divisions. G1 phase, S-phase, the G2 phase and M-phase. The
genome replicates in S-phase and the nucleus divides in M-phase. G1 and G2 are gap phases
before DNA replication and nuclear division respectively. Eukaryotic cells have evolved a
complex network of regulatory proteins, known as the cell cycle control system that governs
progression through the cell cycle. The cell cycle control system regulates cell cycle progression
at 3 major regulatory transition, or check points. The first check point is Start in G1, where the
cells commits to cell cycle entry and chromosome duplication. The second is the G2/M
checkpoints, where the control system triggers the early mitotic events that lead to chromosome
alignment on the spindle in metaphase. The third is in the metaphase to anaphase transition,
where the control system stimulates sister chromatid separation, leading to the completion of
mitosis and cytokinesis. The control system blocks progression through each of these check
points if it detects problem inside or outside of the cell. Most cancer cells harbor mutations in the
genes, responsible for the progression from G1- to the S-phase of the cell cycle.
1.1.2 THE RESTRICTION POINT (R)
If cells are deprived of growth factors prior to R, they exit the cell cycle into a state of
quiescence known as G0. One of the rationales for G0 (exiting the cell cycle exit, rather than
arrest) is that it takes more time to transition from G0 to S-phase than it does to transition from
the end of mitosis (start of G1) to S-phase [1, 2]. Anders Zetterberg and colleagues have
carefully mapped the time for post-mitotic cells to reach R to about 3 to 4 hr – a time course that
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was remarkably constant for virtually all cell lines examined [3-5]. Therefore, it was suggested
that G1 be divided into two portions - G1-pm for G1-post-mitotic, and G1-ps for G1-pre-S4 (Fig.
1). Whereas, G1-pm is relatively constant, G1-ps are variable – and it is this variability in the
duration of G1-ps that contributes to confusion. Pardee’s early studies used Swiss 3T3 cells,
which have a relatively short G1 of about 5½ hr [6, 7] Consistent with Zetterberg’s work, R was
approximately 3½ hr after mitosis [6, 7] and therefore, approximately 2 hr prior to S-phase. And
2 hr prior to S is where most texts place R – that is R is positioned relative to S-phase entry,
rather than relative to the end of mitosis. However, for most cell lines, G1 is significantly longer
than the 5½ hr observed for Swiss 3T3 cells. Therefore, since R is consistently 3½ hr after
mitosis [5] the time from R until S-phase is much longer than the 2 hours [8].

Figure 1: Mammalian cell cycle (Adapted from [8]). The mammalian cell cycle originally
described as consisting of two parts – mitosis and interphase. During interphase the genome is
duplicated and was called S-phase for synthesis. G1 and G2 were proposed as the gaps between
mitosis and S-phase, and between S-phase and mitosis respectively. G1 is usually where critical
decisions are made as to whether to enter a resting quiescent stage known as G0, or continue
cycling and commit to replicating the genome and mitosis. The point in G1 where this growth
factor-dependent decision is made is known as the Restriction Point (R). G1 has been described
as consisting of two parts on either side of R where the first part of G1 is known as G1-pm for
post-mitotic, and the second part is known as G1-ps for pre-S.
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Studies by Hartwell and colleagues described a site in late G1 in yeast cells where cells
arrest in the absence of sufficient nutrients for the cell to double its mass [9]. This site was called
START and has been referred to as the equivalent of the mammalian R. However, START is not
sensitive to growth factors – the yeast cells are responding to nutrient availability. This
significant difference may provide an important lead for resolving the confusion as to what R
actually represents and where R is located in G1. Of significance, passing START is dependent
on TOR [10] which has been widely implicated in sensing nutritional needs in both yeast and
mammalian cells [11, 12]. Blenis’ group, as well as others, demonstrated that rapamycin
treatment in mammalian cells leads to cell cycle arrest in G1 [13, 14] at a site that is consistent
with START. The studies described by Blenis’ group indicate that suppressing mTOR results in
arrest late in G1. Importantly, cells arrested with rapamycin were smaller than the untreated
cells, [13, 14] consistent with a role for mTOR as a nutritional sensor that restricts cell growth in
the absence of sufficient nutrients. Thus, the site in G1 where rapamycin arrests cells prior to
cell growth may be more equivalent to the yeast START, which is dependent on TOR and
nutrient availability [8].
Existing data are consistent with R and START being distinguishable from each other in
that R is a growth factor-sensitive site where cells receive instructions to avoid cell cycle exit
into quiescence, and START senses whether there is sufficient nutrition for a cell to double in
size prior to committing to replicate the genome and divide. The ability of rapamycin, which
inhibits the nutrient sensing mTOR, to induce arrest in late G1 indicates that START may be
conserved in mammalian cells – but not as R. Instead, START may be conserved in mammalian
cells as a distinct checkpoint that senses nutritional sufficiency. This mTOR-dependent
checkpoint could more appropriately be referred to as a “Cell Growth” checkpoint. Importantly,
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signals that regulate mTOR and cell growth apparently need to be dysregulated in tumor genesis
[8].
1.1.3 REGULATION OF G1 PROGRESSION
The proposal of a Cell Growth checkpoint warrants a brief overview of what is known
about the control of G1 cell cycle progression. There are several in-depth reviews on this subject
(Sherr, 2000; Sherr and McCormick, 2002; Ho and Dowdy, 2003; Blagosklonny and Pardee,
2002; Giacinti and Giordano, 2006; and others), so this discussion will be restricted to
controlling progression through R and the proposed Cell Growth checkpoint. Key regulators of
cell cycle progression are the cyclins – proteins that interact with and activate specific Cyclin
dependent kinases (CDK). There are two major classes of G1 cyclins – cyclin D and cyclin E.
Cyclin D interacts with either CDK4 or CDK6 and cyclin E partners with CDK2. Cyclin D,
partnered with either CDK4 or CDK6, phosphorylates the retinoblastoma tumor suppressor Rb to
generate what has been called hypo-phosphorylated Rb. Hypo-phosphorylated Rb exists in a
complex with E2F family transcription factors that are critical for progression into S-phase. The
association of E2F with Rb is dependent on the hypo-phosphorylation provided by cyclin DCDK4/6, and therefore, the suppression of E2F by Rb is dependent on cyclin D-CDK4/6. Cyclin
D is suppressed by a CDK inhibitor p21. A very well studied tumor suppressor p53 stimulates
the transcription of p21 which helps in causing cell cycle arrest. Cyclin E-CDK2, on the other
hand is suppressed by the CDK inhibitor p27Kip1, but p27Kip1 also interacts with cyclin DCDK4/6 and is required for its activity. As cyclin D levels increase, more p27Kip1 is sequestered
and thus ultimately cyclin E-CDK2 loses its inhibitory p27Kip1 to the more abundant cylin DCDK4/6. It has been proposed that the sequestration of p27Kip1 by cyclin D-CDK4/6 contributes
to the activation of cyclin E-CDK2 [15]. Activated cyclin E-CDK2 phosphorylates Rb to
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generate a hyper-phosphorylated Rb, which liberates E2F to initiate the transcription of genes
needed for progression into S-phase – including cyclin E. Since the phosphorylation of Rb by
cyclin D-CDK4/6 is required prior to the phosphorylation of Rb by cyclin E-CDK2, it has been
proposed that Rb serves as a cell cycle clock that controls progression through critical regulatory
points in G1 mediated by its sequential phosphorylation, which is shown schematically in Fig. 2
[16].

Figure 2: Rb and G1 cell cycle progression (Adapted from [8]). Rb exists in different states
of phosphorylation – unphosphorylated, hypophosphorylated, and hyperphosphorylated. The
hypophosphorylated state occurs after phosphorylation by cyclin D-CDK4/6 and this leaves Rb
associated with E2F family transcription factors such that E2F is unable to activate transcription.
Rb becomes hyperphosphorylated after the activation of cyclin E-CDK2. At this point E2F
dissociates from E2F and can initiate the transcription of genes required for progression into Sphase. One of the genes activated by E2F is cyclin E generating a positive feedback loop to aid
in the progression through G1-ps.
The location of R according to both Zetterberg and Pardee is about 3½ hr after mitosis, a
point in G1 where cyclin D levels increase. Growth factors that facilitate passage through R
stimulate increases in cyclin D levels. Activated Ras, which mimics growth factor signals, also
stimulates an increase in cyclin D levels. Importantly, the transformation of cells by Ras is
dependent on cyclin D [17]. Thus, there is a clear correlation between cyclin D levels and
passage through R. Whether the hypo-phosphorylation of Rb by cyclin D-CDK4/6 has any role
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in passing R is not clear in that it has been reported that hypo-phosphorylation of Rb occurs after
R passage [4]. However, in the absence of Rb, cells apparently do not exit the cell cycle when
deprived of growth factors, indicating that inactivating Rb may impact on the ability to enter
quiescence [8].
After progression through the cyclin D-dependent portion of the cell cycle, cyclin E
becomes activated and Rb becomes hyper-phosphorylated by cyclin E-CDK2. At this point, Rb
no longer suppresses E2F and E2F can then stimulate the expression of many genes needed for
progression into S-phase. Another substrate of cyclinE-CDK2 is its inhibitor, p27Kip1. S-phase
kinase associated protein 2 (SKP2) is an E3 ubiquitin ligase that causes phosphorylation of the
CDK inhibitor p27 [18]. Phosphorylation of p27Kip1 targets it for ubiquitination and degradation
by the proteasome. At this point, cyclin D is no longer required for sequestering p27Kip1 as a
means of activating cyclin E-CDK2. This creates a positive feedback loop whereby cyclin ECDK2 suppresses Rb and liberates E2F, which then increases the level of cyclin E such that
cyclin E-CDK2 can continue to suppress Rb and keep p27Kip1 targeted for degradation. The cells
can now progress through the last part of G1 into S-phase. This regulatory point of the cell cycle
has been referred to as R in several reviews and texts [19-21]. However, this site is also where
START of the yeast cell cycle is located [8].
As indicated above, START is a site in the yeast cell cycle that senses nutrition and is
dependent on TOR. Moreover, passage through the growth factor dependent R occurs long
before the increase in cyclin E levels and increased activity of CDK2 [3]. Thus, there is a clear
distinction as to what R represents and where R exists in G1. Of interest is the regulation of cell
cycle progression by transforming growth factor-β (TGF-β), which suppresses cell cycle
progression late in G1 and also increases levels of cyclin E-CDK2 inhibitor p27Kip1. Therefore,
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TGF-β can suppress cell cycle progression at the cyclin E-dependent point late in G1 that is
equivalent to START. Defects in p27Kip1 expression are also common in human cancer [22]. A
critical aspect of TGF-β-induced cell cycle arrest is the suppression of Myc expression [23],
which is consistent with Myc being a downstream target of mTOR and Phospho Lipase D (PLD)
signals – both of which suppress TGF-β signaling. Transformation studies with phorbol esters
also implicate a late G1 checkpoint mediated by TGF-β. Tumor promoting phorbol esters
cooperate with activated Ras, but not elevated Myc expression, to transform primary rodent
fibroblasts [24]. This would implicate the tumor promoters as progression factors for passage
through G1-ps and the putative Cell Growth checkpoint. The tumor promoting effects of
phorbol esters are the result of suppressing protein kinase Cδ (PKCδ) expression and
significantly [25, 26], PKCδ is required for the TGF-β signals that induce cell cycle arrest [27].
Thus, the effect of tumor promoting phorbol esters can be linked to their ability to facilitate
passage through the G1-ps checkpoint mediated by TGF-β. In summary, genetic studies that
reveal a requirement for elevated mTOR signaling in cell transformation, coupled with the ability
of mTOR to suppress TGF-β signals, strongly indicate that this late G1 checkpoint is
distinguishable from the site regulated by cyclin D, which is elevated in response to growth
factor signals and activating mutations to Ras [8].
1.1.4 THE CELL GROWTH CHECK POINT IN MAMMALIAN CELLS
START was originally described as a commitment point late in G1 where nutritional
sufficiency and cell size was established prior to committing to replicating the genome and
cytokinesis [9, 28]. Cyclin E was discovered as being able to complement G1 cyclin mutants in
S. cerevisiae, thereby facilitating passage through START [29, 30]. The connection between
cyclin E and mTOR via TGF-β signaling [27, 31, 32] links cyclin E to nutritional sensing in that
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mTOR is activated by amino acids and is suppressed by low ATP levels [11, 33]. The lack of
essential amino acids, similar to rapamycin treatment, results in G1 cell cycle arrest. Importantly,
reentry of Swiss 3T3 cells into the cell cycle upon restoring amino acids is significantly faster
(2hr) than when cells have entered quiescence upon being deprived of growth factors (12 hr) [7].
Exiting quiescence and entering S- phase generally takes much longer than G1, which is part of
the rationale for postulating G0 [1, 2]. The difference between recovery from amino acid
starvation versus serum deprivation also clearly distinguishes R from the mTOR-dependent
checkpoint [8].
Signals activated by insulin and insulin-like growth factor-1 (IGF1) also provide a
response to nutritional sufficiency [34]. Stiles et al [35] provided a model for commitment and
progression of cells from G0 into S-phase whereby transient exposure to platelet-derived growth
factor (PDGF) was sufficient to get cells to “commit” to cell cycle entry, but “progression”
through the rest of G1 required continuous treatment with IGF1. This early study is consistent
with a model where PDGF is needed for entrance into the cell cycle and IGF1 required for
passage through G1-ps. PDGF stimulates increased expression of cyclin D [36] while IGF1
activates PI3K and both mTORC1 and mTORC2 [37]. Thus, the commitment-progression model
for G1 cell cycle progression is consistent with a need to pass through both a growth factor
cyclin D-dependent R, and an mTOR and cyclin E-dependent Cell Growth checkpoint [8].
Shaw and colleagues have recently reported that the AMP-dependent kinase (AMPK)
phosphorylates Raptor directly and is required for suppression of mTORC1 [38]. As AMPK has
been widely implicated in sensing metabolic capability in the cell, a “metabolic checkpoint”
mediated by AMPK and mTORC1 has been proposed [39]. A checkpoint mediated by AMPK
and mTORC1 would be considered part of the Cell Growth checkpoint. It is also worth noting
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that PI3K signaling, which contributes to mTOR activation, has also been linked to the
regulation of growth and metabolism [40]. Thus, a significant body of evidence is emerging that
implicates mTOR as a critical mediator of cell cycle progression through a late G1 checkpoint
that can be distinguished both functionally and temporally from R. A model for control of G1
cell cycle progression is shown in Fig. 3. This model for G1 cell cycle progression is consistent
with the complement of genetic changes that occur in cancer cells and with the genetic
requirements for the transformation of human cells [8].

Figure 3: G1 cell cycle checkpoints (Adapted from [8]). Progression through G1 of the cell
cycle is shown as having three major obstacles for which specific genetic alterations need to
occur during tumor genesis. After completing mitosis, the first obstacle is passing R where cells
avoid quiescence. Passage of this site is dependent on growth factor instructions or in the case of
a cancer, a mutation to Ras or another component of the Ras pathway that leads to cyclin D
expression. After passing R, the next obstacle involves the activation of signals that indicate
sufficient nutrients for the cell to double in mass. We refer to this site the “Cell Growth”
checkpoint. A focal point of this checkpoint is mTOR, which suppresses TGF-β signaling,
which stimulates the expression of p27Kip1, which suppresses cyclin E-CDK2.
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1.2 MAMMALIAN TARGET OF RAPAMYCIN (mTOR)
1.2.1 mTOR OVERVIEW
mTOR- the mammalian target of rapamycin is a critical nutritional and energy sensor in
cells which is found to be dysregulated in complex diseases including most cancers, obesity,
diabetes, aging and neurological disorders. mTOR plays a critical role in cell cycle progression
and cell survival [43, 44].

mTOR is a serine threonine protein kinase that belongs to

phosphatidynilositol 3 kinase (PI-3K) related protein kinase family that is conserved from yeast
to mammals [45]. mTOR exists in two complexes, mTORC1 and mTORC2. These complexes
are formed by binding to specific proteins most significantly Raptor and Rictor respectively [46].
mTOR is found dysregulated in most cancers.
TOR was originally discovered in yeast [47, 48]. It was only after several years that its
orthologue was found in mammals [49-52]. Recently an alternate name for mTOR has been
introduced by its database curators - the mechanistic target of mTOR (MTOR). The
interchangeability of mTOR/MTOR, mammalian/mechanistic is not widely accepted yet. Since,
mTOR is largely accepted as the mammalian target of rapamycin, in this work I shall be
referring mTOR as the same.
1.2.2 THE STRUCTURE OF mTOR
mTOR is essentially a 290 kDa multi-domain protein belonging to PI-3K family. mTOR
is composed of an N-terminal HEAT (Huntington elongation factor 3, alpha regulatory subunit
of protein phosphatase 2A and TOR1) domain, a FAT (FRAAT-ATM-TRAAP) domain, FATC
domain and a C-terminal kinase domain. mTOR also contains a FKBP12/rapamycin binding
domain called the FRB domain in between its FAT and kinase domain. HEAT and FAT domains

11	
  
	
  

are required for protein-protein interactions. The FATC domain responds to redox potential [5355]. A schematic of the structure is shown below in Fig 4.

Figure 4: Domain organization of mTOR (Adapted and modified from [46]). The domain
organization of mTOR resembles that of PIKK family. It has HEAT, FAT, FRB, FATC and
kinase domain.
1.2.3 THE mTOR COMPLEXES
mTOR exists in two complexes mTOR complex 1 (mTORC1) and mTOR complex 2
(mTORC2). These complexes are composed of some shared and some unique partners. Each
complex other than the mTOR subunit also has mammalian lethal wit sec-13 protein 8 (mLST8),
DEP domain containing mTOR interacting protein (DEPTOR) which is critical for mTOR
assembly and signaling and is a negative regulator of mTOR and Tti1/Tel2 complex which
regulates the stability and assembly of mTOR. mTORC1 contains two unique partners, one of
which is the regulatory associated protein of mTOR or RAPTOR. Raptor is a scaffolding protein
which regulates the substrate binding of mTOR. The other unique partner of mTORC1 is the
proline rich Akt substrate 40 kDa (PRAS40) which is also a negative regulator of mTORC1.
mTORC2 on the other hand has three unique partners which are rapamycin insensitive
companion of mTOR or RICTOR, which is a scaffolding protein and facilitates mTOR’s binding
to its substrates, mammalian stress activated MAP kinase protein 1 (mSin1) and proteins
observed with rictor 1 and 2 (protor 1/2), both of which are involved with a activation of the
downstream target of mTOR which is SGK1 [56, 57]. In addition both complexes interact with a
lipid metabolite called phosphatidic acid (PA) that is shown to be required for the stability of the
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complex and binds to mTOR in a manner that is competitive with rapamycin [58-61]. Fig 5
below shows a schematic representation of the complexes.

Figure 5: mTORC1 versus mTORC2 (Adapted from [56]). Distinct partner, protein and
substrates distinguishing the two mTOR complexes.
1.2.4 mTOR SIGNALING PATHWAY
Upstream signaling: mTORC1 complex receives its signals from the PI-3K- Akt pathway.
Activation of PI-3K by several growth factors result in conversion of PIP2 to PIP3. PTEN
(Phosphatase and tensin homolog deleted from chromosome 10) catalyzes the reverse reaction.
Activation PIP3 activates its downstream regulator Akt by phosphorylating the later at position
threonine 308.Akt is also activated by mTORC2 at position serine 473 Activated Akt in turn
suppresses the tuberous sclerosis complex (TSC1/2), which is a GTPase activating protein that
suppresses the GTPase Rheb [62]. Rheb is required for the activation of mTORC1 [63]. Rheb
also activates PLD1 [64] which in turn activates mTORC1 [65, 66]. AMPK is a negative
regulator of mTOR. It inactivates mTOR by activating TSC1/2 and also by phosphorylating
raptor [38]. mTOR’s position downstream of PI-3K provides for its direct link to carcinogenesis.
The mTOR pathway is represented schematically in Fig 6.
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Figure 6: mTOR signaling pathways activated in human cancer cells (Adapted and
modified from [8]).The PI3K input involves the generation of PIP3 which recruits and activates
PDK1 and then phosphorylates Akt at Thr308. Akt can then phosphorylate and suppress the
GAP activity of TSC1/2.Suppression of TSC1/2 results in elevated activation of the GTPase
Rheb, which then leads to a complex activation of mTORC1 via the activation of PLD1 and
suppression of FKBP38 whereby elevated PLD activity generates the phosphatidic acid
necessary for the formation of mTORC1 complex and FKBP38 dissociates from mTORC1.
mTOR stimulates ribosomal subunit S6 kinase, which stimulates the translation of many
transcripts including those for Myc. In addition, mTORC1 suppresses TGF-β signals in a manner
that is poorly understood. Suppression of TGF-β signals subsequently leads to higher levels of
cyclin E. This pathway is also impacted by the AMPK, which in combination with the tumor
suppressor LKB1, activates TSC1/2 and suppressing mTOR under conditions where ATP levels
are low and AMP levels are high. AMPK was also shown to phosphorylate Raptor, a protein
associated with mTORC1, leading to the inactivation of mTORC1.Akt is also phosphorylated by
mTORC2 at Ser473 in response to insulin and IGF1 in a PLD-dependent manner.
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Downstream signaling: mTOR has several downstream targets. One of the most widely
studied targets is S6 kinase. mTOR phosphorylates S6 kinase at Threonine 389 (T389) which is
particularly important because substitution of this residue with alanine blocks the activation of
the kinase domain [67]. S6 kinase in turn phosphorylates the ribosomal protein S6, the
component of 40S ribosome [68, 69] that is involved in protein synthesis [70].
Another well understood mTORC1 substrate is 4E-BP1 [70]. 4E-BP1 plays an important
role in translation. 4EBP1 belongs to a family of repressor proteins that bind to eIF4E and inhibit
cap dependent translation. Whether 4E-BP1 will bind to eIF4E depends on the phosphorylation
status of the former. Hypo phosphorylated 4E-BP1 binds to eIF4E and prevents its association
with the cap binding of eIF4F thus preventing cap binding translation to occur [71]. The binding
of eIF4E to 4E-BP1 is represented schematically in Fig 7. However when mTORC1 is activated
by the presence of adequate growth factors, amino acid and energy, it phosphorylates 4E-BP1,
hierarchically on threonine 37 (T37), threonine 46 (T46), threonine 70 (T70) and serine 65 (S65)
[72, 73]. Upon being hyper phosphorylated 4E-BP1 releases eIF4E; eIF4E then binds to
eukaryotic initiation factor 4G (eIF4G) which recruits the helicase eukaryotic initiation factor 4A
(eIF4A) which is necessary to unwind and is an inhibitory structure of 5’ region of mRNA.
Finally a new complex is formed with eIF4E/eIF4G/eIF4A on the 5’ cap to form a translation pre
initiation complex [74].
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Figure 7: Interaction between eIF4E, 4E-BP1, and eIF4G (Adapted from [74]). In the basal
state, eIF4E is held inactive by 4E-BP1. When a stimulus is received for protein synthesis, 4EBP1 is phosphorylated and dissociates from eIF4E. Free eIF4E binds to eIF4G and facilitates
onset of the initiation phase of mRNA translation.
1.2.5 4E-BP1 IS AN IMPORTANT TARGET FOR EFFECTIVE mTORC1 INHIBITION
The overall role of mTORC1 in the regulation of mRNA translation is very
significant because complete inhibition of mTORC1 function significantly reduces rates
of protein synthesis in proliferating cells [75]. There have been several studies that have
demonstrated the role of S6 kinase in tumor progression [76, 77]. For instance, Zhou showed that
constitutively active S6 kinase increases invasiveness in ovarian cancer cells. However, the
contribution of S6 kinase and S6 to oncogenic action is not widespread. In fact, 4E-BP1 appears
to promote cell cycle progression and cell proliferation more efficiently independent of S6
kinase.
Much evidence supports dysregulation of protein synthesis at the level of 4EBP1/eIF4E as
playing a central role in tumor formation. De-phosphorylated 4E-BP1 can inhibit cell growth and
reverse the transformed phenotype of eIF4E over-expressing cells [78]. Constitutively active 4EBP1 mutants, all phosphorylated sites mutated to alanine cannot be phosphorylated by mTORC1.
This 4EBP1 mutant also blocks myc-induced transformation and prevents tumor growth [13, 14,
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79]. In both cases, the 4E-BP1/eIF4E interaction is enhanced; this leads to a decrease in cell size
and inhibition of cell cycle progression [13]. These data suggests that 4E-BP1 is a major cellular
effector of cell cycle progression and cell proliferation.
While mutated 4E-BP1 inhibits growth, absence of 4E-BP1 promotes growth. As
mentioned before, eIF4E is sequestered and permanently held inactive by a mutant 4E-BP1. In
other words eIF4E is always “free” when 4E-BP1 is absent. Otherwise low in normal cells,
eIF4E levels are over-expressed by loss of 4E-BP1 and translation is dysregulated. Mouse
embryonic fibroblasts (MEFs) lacking 4E-BP1 prevent inhibition of cell cycle progression by
raptor knockdown [80]. Such over-expression has been shown to promote translation of mRNAs
implicated in cell growth, proliferation and survival [81]. Over-expression of eIF4E also
accelerates G1/S-phase progression and confers partial protection from rapamycin [13].
eIF4E was the first translation factor shown to cause malignant transformation when overexpressed in cultured rodent cells [82]. These studies defined eIF4E as an oncogene as it
cooperates with myc to transform primary embryo fibroblasts [83]. On the other hand, increased
eIF4E expression has been associated with tumor formation and progression in cancer including
leukemia, lymphoma, and cancers of several tissues like breast, colon, bladder, lung and prostate.
Overall, these studies indicate that impairing 4E-BP1/eIF4E complex stability plays an
important role in cancer by controlling translation of various transcripts that promote cell
proliferation and tumor genesis.
1.3 RAPAMYCIN
1.3.1 OVERVIEW
Rapamycin is naturally produced by a bacterium Streptomyces Hygroscopicus. It is
essentially a macrolide antibiotic discovered in the Eastern Island of South Pacific. It was
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originally defined as an antifungal compound in 1975 as it caused G1 cell cycle arrest [84] and
later found to possess immunosuppressant properties [48]. Rapamycin’s broad anti proliferative
property led to its discovery as an inhibitor of S6 kinase phosphorylation at T389. Later it was
found that rapamycin also inhibited 4E-BP1 phosphorylation [71]. Only later it was found that
mTOR phosphorylates S6 kinase, this made rapamycin the first defined inhibitor of mTOR.
1.3.2 MECHANISM OF ACTION
Unlike the traditional kinase inhibitors rapamycin is an allosteric inhibitor of mTORC1
working through a gain of function mechanism. Rapamycin interacts with its intracellular
receptor FKBP12 (FK506 binding protein of 12 kDa). This complex of rapamycin and FKBP12
interacts with the FRB (FKB12-rapamycin binding domain) domain, a short sequence lying
upstream of carboxyl terminal of mTOR [84]. Binding of rapamycin-FKBP12 complex with the
FRB domain of mTOR prevents mTOR from interacting with its binding partner Raptor, thus
disrupting mTOR signaling. Phosphatidic acid (PA), a lipid second messenger activates mTOR
by binding to its FRB domain. Rapamycin is shown to compete with PA to bind to the FRB
domain of mTOR [60].
The work by Jacinto et al showed that FKBP12- rapamycin complex do not bind to
mTORC2 hence rapamycin is thought to inhibit only mTORC1.In fact, Rictor is an acronym that
defines its response to rapamycin: (R) rapamycin (I) insensitive (C) companion of TOR.
However later Sabatini’s group has shown that if cells are exposed to a prolonged rapamycin
treatment then rapamycin can actually work on mTOR2 as well by disassembling the mTORC2
complex [85]. At a glance it might seem that rapamycin’s effect on both mTOR complexes can
elevate its therapeutic implications but it is also known that rapamycin activates survival signal
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by activation Akt phosphorylation [86]. Therefore elucidating rapamycin’s mechanism of action
has implications for clinical efficacy and effectiveness.
1.3.3 THE EFFICACY OF RAPAMYCIN
The initial stages of clinical trial of any drug are designed to test the efficacy instead of the
effectiveness or the relevance of the drug under trial. Although the apoptotic and antiproliferative effects of rapamycin has been demonstrated by Vivanco et al in head and neck
squamous cell carcinoma, overall it has been proven to be only modestly efficacious. Because of
rapamycin’s poor solubility a large number of analogs of rapamycin (rapalogs) have been
developed and are being tested in clinic.	
   Rapamycin and rapalogs have been approved as
immunosuppressive agents to blunt organ transplant rejection, in cardiology to reduce restenosis
following angioplasty, and in oncology to treat renal cell carcinoma or are in various stages of
clinical trials [87]. In 2007 the rapalog temsirolimus was approved by FDA for the treatment of
advanced stage renal cell carcinoma, making it the first mTOR inhibitor approved for cancer
therapy. Recently another rapalog everolimus was approved for the treatment of tuberous
sclerosis, an autosomal dominant disorder characterized by hamartomas in various organs
including the brain [88].
1.3.4 SECOND GENERATION OF mTOR INHIBITORS
In the recent times a lot of ATP competitive catalytic mTOR inhibitors have been
introduced with the idea of dual inhibition of mTORC1 and mTORC2 namely Torin 1, PP242,
Ku-0063794, WAY600, AZD8055 [89]. Chresta et al showed that these catalytic inhibitors are
small molecule which bind directly to the ATP-binding domain of mTOR and thus block
mTOR’s ability to phosphorylate its downstream targets. As expected these second generation
inhibitors can inhibit cell growth and proliferation invitro and tumor growth in vivo to an extent
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much better than rapamycin [90-92]. They can inhibit 4E-BP1 phosphorylation more efficiently
than rapamycin thus causing better inhibition of cap dependent translation. Moreover, these
catalytic inhibitors induce significantly broader impact upon translation. Several genes playing
critical role in tumor progression are affected only upon complete inhibition of mTOR by these
catalytic inhibitors [93].
The second generation inhibitors of mTOR have more prospect than rapamycin because of
the ability of the former to suppress both mTORC1 and mTORC2. The mTOR kinase inhibitor
Torin1 developed in David Sabatini’s lab was shown to be a better translation repressor than
rapamycin [89]. Surprisingly enough their group also showed that these inhibitors were
successful in inhibiting proliferation even in mTORC2 deficit cells. They suggested that the
inhibition of proliferation was caused by the suppression of rapamycin resistant functions of
mTORC1 [89].
Another reason for the kinase inhibitors of mTOR could not be that wide spread as
expected due to its pretty high toxicity. The concentration that ensure efficacy was not tolerable
to the patients. Thus, their promising therapeutic mechanism has not yet proved to be beneficial
in the clinic. This calls for elucidating the complete potential of rapamycin. Thus, Rapamycin’s
potential as an anticancer drug requires further investigation.
1.4 TRANSFORMING GROWTH FACTOR-β
1.4.1 OVERVIEW
Transforming Growth factor-β (TGF-β) belongs to the superfamily of TGF-β and is a
multifunctional autocrine/paracrine growth regulator [94]. Almost all cell types either produce or
secrete TGF-β or have receptors that respond to its signaling. TGF-β is known to have a role in
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an array of biological processes like embryonic development, wood healing and angiogenesis.
Studies have shown that under normal conditions, TGF-β restricts cell growth, differentiation
and cell death [95-97]. TGF-β was originally identified as a factor that could transform normal
cells [98]. After the confirmation of TGF-β as a potent growth inhibitor of epithelial cells it
became clear that TGF-β is a tumor suppressor for early stages of cancer. However many human
carcinomas overexpress TGF-β and this is associated with poor patient prognosis and increased
frequency of metastasis [99]. Thus, there is a growing body of evidence for a duality of function
for the role of TGF-β in cancer that is “stage specific”.
1.4.2 TGF-β AS A TUMOR SUPPRESSOR
In order to maintain equilibrium, rapidly proliferating epithelial cells need to maintain a
delicate balance between increase in cell number due to cell proliferation and cell death by
apoptosis [100]. Although there are several studies identifying TGF-β as an oncogene, it has also
been shown that TGF-β plays a major role in the inhibition cell growth and induces apoptosis.
fact that TGF-β primarily inhibits the proliferation of many cell types attributed to this cytokine
and its signaling pathway a tumor suppressor role [101, 102]. During tumor progression, cancer
cells tend to acquire resistance against the growth inhibitory effects of TGF-β [103]. For
instance, when TGF-β is over expressed in keratinocytes of mice and their skin is exposed to
chemical carcinogens, TGF-β initially inhibits the formation of benign skin tumors. However, in
the benign tumors that form, progression to invasive carcinomas is increased [104]. The tumor
suppressive effects of TGF-β have been well studied in transgenic mice models. Hemizygous or
homozygous TGF-β-null animals show increased incidence of chemically or spontaneously
induced tumors, respectively [105]. Similarly, targeting a dominant negative TGF-β receptor to
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mammary or skin epithelia also enhances tumor genesis whereas TGF-β-overexpressing mice
have decreased incidence of tumors [106].
1.1.3 TGF-β AS A TUMOR PROMOTER
The major cause of mortality in cancer is the formation of metastases, the spread of tumor
cells to distant sites in the body via the body fluid like lymph system or the bloodstream. A
known critical regulator of breast tumor growth and metastasis formation is TGF-β. During the
course of the disease, a change in TGF-β -responsiveness of the tumor cells often occurs. TGF-β
then leads to the acquisition of a more invasive and tumorigenic cell phenotype with an elevated
potential to form metastasis. The molecular basis for this change is mostly unknown [106].
In many cases, tumor cells secrete non-physiological levels of TGF-β which may affect in
an autocrine manner, the differentiation of tumor cells and the surrounding cellular environment
in a paracrine manner, leading to tumor progression and metastasis [94, 98]. The remaining
TGF-β affects the cell in two ways. First, it promotes angiogenesis (the overgrowth of blood
vessels). Tumors use angiogenesis to grow new blood vessels that sustain their growth and
metastasis. Second, excess TGF-β suppresses T cells and other components of the immune
system that would normally attack aberrant cells [107]. TGF-β has been implicated in each one
of the hallmark steps to cancerous phenotype portrayed [100].
One aspect of tumor cell biology that is thought to contribute to metastasis is epithelial-tomesenchymal transformation (EMT) [108]. EMT allows cells to migrate out of the primary
tumor into circulation. TGF-β- induced EMT has been reported in Ras-transformed breast,
ovarian and skin cancer [109]. Conversely, transfection of dominant negative TGF-β receptors
into tumors inhibited this transformation. Tumor angiogenesis is vital for tumor growth and
invasion since blood deliver nutrients and oxygen into the tumor and give the tumor access to
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circulation. In human breast tumors, high levels of TGF-β are associated with increased micro
vessel density, and poor prognosis [110]. TGF-β has also been shown to induce expression of the
angiogenesis-inducing factor vascular endothelial cell growth factor (VEGF) [111] and local
administration of TGF-β neutralizing antibody strongly reduced VEGF secretion and tumor
angiogenesis in nude mice [112]. The dual role of TGF-β is schematically represented in Fig 8.

Figure 8: Dual role of TGF-β signaling in Cancer progression (Adapted from [106]).
Various alterations in the TGF-β signaling pathway can contribute to increased tumor
progression, invasion and metastasis. Two general routes can be taken :( 1) Early genetic loss of
signaling components, such as TβRII, leads to rapid growth. Increased cell division increases the
probability of further cancer contributing mutations and cytogenetic changes that ultimately
drive tumor progression. (2) More frequently, the TGFβ signaling pathway remains intact but is
perturbed by other mechanisms. Altered Smad signaling leads to a direct increase in tumor cell
plasticity, invasion and metastasis, involving reversible epithelial-to-mesenchymal
transformation (EMT). Thick lines indicate the more prevalent pathway.
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1.4.4 TGF-β SIGNALING PATHWAY
The onset of TGF- β signaling begins with the binding of TGF-β to the TGF-β receptor II
(TβRП) receptor kinase, which gets activated and in turn phosphorylates and couples with TGFβ receptor I (TβRІ) receptor kinase rendering it active. TβRІ can then phosphorylate downstream
effectors of the TGF-β signaling pathway which are the Smad family proteins. Smad-2 or Smad3 are phosphorylated by TβRІ at their C-terminal SSXS residues as shown in Fig 9. These Smads
are called receptor Smads (R-Smads). Phosphorylated Smad-2 and Smad-3 form a complex with
Smad-4 which is known as the co-Smad and together this Smad complex translocate to the
nucleus and begin the transcription of various cell cycle regulated genes like p21 and p27 that are
required to cause a cell cycle arrest [113]. TGF-β is negatively regulated by Smad 6 and Smad 7.
These Smads are called “the early response genes”. They bind to activated TβRІ, thus blocking
its phosphorylation and activation of R-Smads. Smad independent signals mediated by TGF- β
has also been reported which involves pathways like ErK, JNK, Src Kinase, MAPK, PI3K/Akt
and Rho-like GTPase signaling pathway [114]. TGF-β signaling is often found compromised in
many pancreatic and colon cancer cells.
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Figure 9: TGF-β signaling pathway (Adapted from [115]). TGF-β regulates the growth and
proliferation of cells. The TGF-β receptor includes type 1 and type 2 subunits that signal through
the SMAD family of transcriptional regulators. Binding of TGF-β induces the phosphorylation
and activation of the TGFβRI by the TGFβRII. The activated TGFBRI phosphorylates SMAD2
and SMAD3, which binds to the SMAD4, which binds to the SMAD4 mediator to accumulate
into the nucleus and form complexes that regulate transcription. SMADs regulate transcription in
several ways, including binding to DNA, interacting with other transcription factors and
interacting with transcription co-repressors and co-activators.
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CHAPTER II:
PROJECT RATIONALE
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2.1 THE CYTOSTATIC AND CYTOTOXIC ROLE OF RAPAMYCIN
Our lab has reported previously that while high dose rapamycin treatment induced
apoptosis in MDA-MB-231breast cancer cells in the absence of serum, in the presence of serum,
high dose rapamycin treatment induced G1 cell cycle arrest [116]. Other studies have shown that
low dose nano-molar concentrations of rapamycin can cause G1 cell cycle arrest [13, 117-119]
however, it has been noted that rapamycin may only slow cell cycle progression through G1 at
the nano-molar concentrations used [120, 121] Yellen et al [122] examined the rapamycin doses
required to block G1 cell cycle progression of MDA-MB-231 cells and the less malignant MCF7 breast cancer cell line. They found that concentrations of rapamycin up to 200 nM slightly
reduced the incorporation of thymidine in the MDA-MB-231 cells, but 20 µM rapamycin
dramatically suppressed uptake of thymidine (Fig. 10). Thymidine incorporation assay is done
by measuring the amount of thymidine was incorporated in the newly synthesized DNA.
Progression of the MCF-7 cells into S-phase was more sensitive to nano-molar levels of
rapamycin, but like the MDA-MB-231 cells, complete G1 arrest required 20 µM rapamycin (Fig.
10) [122]. Thus, the studies by Yellen et al showed that while low nano-molar rapamycin
concentrations retard G1 cell cycle progression, micro-molar concentrations caused a complete
G1 arrest [122].
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Figure 10: Differential suppression of G1 cell cycle progression by low and high dose
rapamycin treatment (Adapted from [122]). MDA-MB-231 and MCF-7 cells were plated and
treated with nocodazole for synchronizing the cells at G1 phase of the cell cycle. The
synchronized cells were then treated with different doses of rapamycin after which a thymidine
incorporation assay was performed.
In contrast to the rapamycin-induced G1 cell cycle arrest observed in the presence of
serum, our lab has previously shown that in the absence of serum, high-dose rapamycin
treatment causes apoptosis [27, 123]. Studies by Yellen et al has shown that a high dose of
rapamycin causes apoptosis in MDA-MB-231 cells in absence of serum (Fig 11) as indicated by
the cleavage of the caspase 3 substrate poly ADP ribose polymerase (PARP) [122]. Thus, high
dose rapamycin causes cell cycle arrest in presence of serum and cell death in absence of serum.

Figure 11: High dose rapamycin causes apoptosis in absence of serum in MDA-MB-231
cells (Adapted from [122]). MDA-MB-231 cells were plated and treated with DMSO (D) or
rapamycin at indicated doses and harvested after 4 hours. Cell lysates were collected and
immunoblotted with PARP antibody.
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2.2 EFFECTS OF LOW AND HIGH DOSE RAPAMYCIN
It has been already well established that rapamycin inhibits mTORC1 as indicated by
suppression of the phosphorylation of S6 kinase at low nM doses [120]. Prior studies in lab have
also shown that rapamycin can inhibit S6 kinase phosphorylation in MCF-7 cells in as low as
0.5nM of rapamycin [58]. However recent studies by Yellen et al showed that a high dose or 20
µM doses of rapamycin is required to inhibit 4EBP1 phosphorylation at position Threonine
37/46 [122].
As shown in Fig. 12, S6 kinase phosphorylation at the mTORC1 site at T389 was sensitive
to 20 nM rapamycin [122] .
4E-BP1was sensitive to rapamycin; however there were profound differences in the doses
needed to suppress the multiple sites on 4E-BP1. Phosphorylation at T70 was sensitive to doses
of rapamycin that suppressed S6 kinase phosphorylation, however phosphorylation of T37/46
and S65 were sensitive to the higher doses of rapamycin (Fig 12) [122]. Thus there is an apparent
difference in the ability of rapamycin to phosphorylate S6 kinase and the different sites of 4EBP1.
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Figure 12: Differential effects of low and high dose rapamycin in MDA-MB-231 cells
(Adapted from [122]). (A) MDA-MB-231 cells were plated in regular medium. 24 hours later,
at 90% confluence, cells were exposed to 0% serum and treated with DMSO (D) or rapamycin
(Rapa) at the indicated concentrations for 4 hours.
It has been reported that nano-molar rapamycin concentrations disrupt the
association of mTOR with Raptor, a critical component of the mTORC1 complex [124]
However, co-treatment with a cross-linking reagent in lysis buffer maintained the mTOR-Raptor
association – suggesting that low dose rapamycin treatment weakens, but does not abolish the
association between mTOR and Raptor. This finding suggests that low dose rapamycin
treatment disrupts the structure of mTORC1 sufficiently to inhibit phosphorylation of S6 kinase,
but not 4E-BP1. Yellen et al [122] examined the association of mTOR with Raptor in the
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presence of low (200 nM) and high (20µM) rapamycin doses with and without crosslinking. As
shown in Fig. 13A, low-dose rapamycin treatment partially dissociated mTOR from Raptor, and
as reported previously [60, 124] the crosslinking reagent reversed this effect and rescued the
association between mTOR and Raptor. In contrast, high-dose rapamycin proved to irreversibly
dissociate mTOR from Raptor as crosslinking failed to rescue the complex association. These
data suggest that the differential effects of high and low dose rapamycin treatment on mTORC1
is due to differential disruption of the mTORC1 complex where low doses loosely disrupt the
structure of mTORC1 such that S6 kinase is no longer recognized as a substrate, and high doses
completely dissociate the complex such that 4E-BP1 is no longer recognized. A schematic
representation in Fig. 13B, shows that low dose of rapamycin partially dissociates mTOR from
raptor and can inhibit only S6 kinase phosphorylation. High dose rapamycin on the other hand
completely dissociates mTOR from raptor and thus can inhibit both S6 kinase and 4E-BP1
phosphorylation. [122]. This data highlights the importance of high dose rapamycin.
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Figure 13: A model for the differential sensitivity of mTORC1 substrate phosphorylation
by rapamycin (Adapted from [122]). (A) After platting cells were exposed to 0% serum and
treated with indicated rapamycin concentrations for 4 hours. Cells were harvested and then lysed
in the absence or presence of DSP crosslinking reagent and immunoprecipitated with mTOR.
The immunoprecipitates were then subjected to Western blot analysis using either mTOR or
Raptor antibody. (B) Rapamycin at low dose partially dissociates mTOR from raptor and inhibits
only S6 kinase phosphorylation. High dose of rapamycin completely dissociates mTOR from
raptor and thus can inhibit both S6 kinase and 4E-BP1 phosphorylation.
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2.3 DEFECTIVE TGF-β SIGNALING SENSITISES CELLS TO RAPAMYCIN
Studies by Gadir et al [27] have shown that upon pre-treatment of serum with a
neutralizing anti-TGF-β, rapamycin induced both cell death and PARP cleavage as shown in Fig
14A. To further establish that the anti-TGF-β antibody used was blocking TGF-β signaling, they
examined the effect of this antibody on Smad2 phosphorylation, which occurs in response to
TGF-β [125]. As shown in Fig 14B, the anti-TGF-β antibody also suppressed Smad2
phosphorylation induced by serum. These data indicate that TGF-β in serum was at least
partially responsible for the ability of serum to suppress the apoptosis induced by rapamycin in
MDA-MB-231 cells. Gadir et al also examined the effect of an inhibitor of the TGF-β receptor
SB-431542 [126] on the ability of rapamycin to induce apoptosis in MDA-MB-231 cells. As
shown in Fig 14C, SB-431542 had the same effect as the neutralizing TGF-β antibody and made
rapamycin an apoptotic drug on the MDA-MB-231 cells. SB-431542 has no effect on cell
viability in the absence of rapamycin. These data indicated that the TGF-β present in serum is
sufficient to suppress the apoptotic effect of rapamycin [116].
Protein kinase Cδ (PKCδ) has been Implicated in signals generated by TGF-β [127, 128].
Therefore to further establish that de-repression of TGF-β signaling was critical for the G1 arrest
induced by rapamycin, Gadir et al examined whether suppression of PKCδ, like suppression of
TGF-β directly, prevented G1 arrest by rapamycin and led to apoptosis. They examined the
effect of rottlerin, a compound that has been shown to suppress PKCδ activity in vivo [25] on
rapamycin treated MDA-MB-231 cells. As shown in Fig 14D, in the presence of rottlerin,
rapamycin induced apoptosis and PARP cleavage in MDA-MB-231 cells in the presence of
serum. Collectively, the data in Fig 14 suggested that the TGF-β present in serum is required for
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the G1 arrest induced by rapamycin in the presence of serum, and that suppression of TGF-β
signaling results in apoptosis instead of G1 arrest in the presence rapamycin [27].

Figure 14: TGF-β signaling is required for the suppression of rapamycin-induced apoptosis
by serum (Adapted from [116]). (A) MDA-MB-231 cells were plated as in Fig 1B and then
shifted to media containing 10% serum, rapamycin (Rap), and anti-TGF-β1 antibody (2 µg/ml)
as indicated. 18 hr later cell viability and PARP cleavage were determined. (B) MDA-MB-231
cells were plated as above and put in media containing either 0% or 10% serum, or 0% serum
and TGF-β. The anti-TGF-β1 antibody was added as indicated. 18 hr later, the levels of indicated
proteins were determined by Western blot. (C) MDA-MB-231 cells were plated as above and
then shifted to media containing 10% serum, rapamycin, and SB-431542 (10 µM) as indicated.
18 hr later cell viability and PARP cleavage were determined as (a). (D) MDA-MB-231 cells
were plated as in Fig 1 and then shifted to media containing 10% serum, rapamycin, and rottlerin
(Rott) as indicated. 18 hr later cell viability and PARP cleavage were determined.
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2.4 PROJECT RATIONALE
Prior studies in the lab by Yellen et al [122] has shown that high dose rapamycin, in
presence of serum causes cell cycle arrest. High dose rapamycin inhibits 4E-BP1
phosphorylation which inhibits eIF4E. However inhibition of eIF4E by siRNA causes apoptosis
in cells both in the presence and in the absence of serum. This is surprising because high dose
rapamycin causes cell cycle arrest in presence of serum [122] and apoptosis in absence of serum
[27]. This indicates that high dose rapamycin does something additional to inhibition of eIF4E
that prevents apoptosis and causes cell cycle arrest, in presence of serum. We know that high
dose of rapamycin inhibits both S6 kinase and eIF4E. Thus, in Chapter 4 we show how the
inhibition of S6 kinase with the inhibition of eIF4E can prevent apoptosis and cause cell cycle
arrest by elevating TGF-β signaling.
Studies by Yellen et al [122] have shown that in presence of serum in MDA-MB-231
cells, rapamycin slows down cell cycle progression till a dosage of 2µM [122]. It is only at 20µM
dose when we see a complete cell cycle arrest (Fig 8). There has not yet been any explanation as
to why we need 20 µM doses of to cause a complete cell cycle arrest. It appears that all cell cycle
arrest causing proteins are not expressed fully. There has been large number of studies showing
major involvement of TGF-β in causing cell cycle arrest. The level of TGF- β signaling goes up
in order to get a complete cell cycle arrest at G1. Work by Harold Moses and colleagues [129]
have shown that rapamycin co-operates with TGF-β to cause complete cell cycle arrest. Studies
have shown that a low dose of rapamycin slows down cell cycle progression. However, it is only
at higher doses that we see a complete cell cycle arrest [122]. Other studies in the lab by Gadir et
al [32] have shown that low

doses of

rapamycin (200nM) was sufficient to cause the

phosphorylation of Smad-2- and Smad-3, the downstream effectors of TGF- β. However,
phosphorylation of Smad-2 and Smad-3 might be sufficient to initiate the onset of TGF- β
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signaling but it is not sufficient to cause a cell cycle arrest. In Chapter 5, I will discuss about the
major cell cycle regulator Rb that plays an important role in causing rapamycin mediated arrest.
Thus, we show that TGF-β and Rb are the two critical players that are required for rapamycin
mediated cell cycle arrest.
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CHAPTER III:
MEHODS AND MATERIALS
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3.1 CELLS AND CELL CULTURE CONDITIONS.
The human cancer cell lines MDA-MB-231 and MCF-7 cells were obtained from the
American Tissue Type Culture Collection (ATCC) and cultured in Dulbecco’s Modified Eagle
Medium (DMEM) (Sigma, Saint Louis, MO, D6429) supplemented with 10% Fetal Bovine
Serum (Sigma F4135).
3.2 ANTIBODIES AND REAGENTS
The following antibodies: Cleaved PARP (9541), p-S6 kinase T389 (9205), S6 kinase
(9202), p-4E-BP1 T37/46 (9459), 4E-BP1 (9452), eIF4E (9742), Smad 2 (5339), Smad 3 (9523),
Smad 4 (9515), p-Rb S780 (9307), Rb (9309), Cyclin D1(2978) and α-Actin(8457)(Cell
Signaling); p-Smad 2 S465/467(Millipore 04-953); p-Smad 3 S423/425 (Abcam ab52903) were
used. Negative control siRNA (Dharmacon), siRNAs targeted against S6 kinase (sc-36165),
eIF4E (sc-35284), Smad 4 (sc-29484) and Rb (sc-29468) (Santa Cruz Biotechnology) were
purchased. Lipofectamine RNAiMax (Invitrogen, 56532) was used for transient transfections.
Rapamycin (R-5000) was obtained from LC Laboratories and the TGF-β inhibitor SB-431542
(S4317) was purchased from Sigma.
3.3 WESTERN BLOT ANALYSIS
Proteins were extracted from cultures cells using MPER (Thermo Fisher scientific-78501).
Equal amounts of proteins were subjected to SDS-PAGE on poly-acrylamide separating gel and
the electrophoresed proteins were transferred to nitrocellulose membrane. The nitrocellulose
membrane proteins were blocked in 5% non-fat dry milk solution in PBST. Membranes were
incubated in primary antibody overnight and secondary antibody for an hour. Detection of
proteins was performed using ECL system (Thermo Fisher Scientific-34080).
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3.4 CELL VIABILITY
Cell viability was determined by counting adherent and floating cells by using a
hemocytometer.
3.4 TRANSIENT TRANSFECTIONS
Cells were plated in 6-well plates in medium containing 10% FBS. The next day (30%
confluence), transfections with siRNAs (100nM) in Lipofectamine RNAiMAX were performed.
After 6 hours, reagents were replaced with fresh 10% FBS and cells were allowed to incubate for
an additional 48 hours.
3.5 FLOW CYTOMETRIC ANALYSIS
Cells were washed and trypsinized. The cell suspensions were recovered and re suspended
in the following fixing solution: 7ml 1X phosphate buffer saline, 2% bovine serum albumin,
5mM EDTA, 0.1% NaN3. 3ml of 100% ethanol was added drop wise. Fixed cells were
centrifuged, washed and then re suspended in 500µl sorting buffer: 1X phosphate buffered
saline, 0.1% Triton-X 100, 2% bovine serum albumin, 5mM EDTA, 40µg/ml propidium iodide,
100µg/ml RNAse A, and incubated at 37C for 30 min. The cells were filtered through 70-µM
mesh to remove all cell aggregates. The DNA content was analyzed by flow cytometry (FACS
Calibur; Becton Dickinson), and percentages of cells within each phase of the cell cycle was
determined using Win Cycle software (Phoenix Flow Systems).
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CHAPTER IV
INHIBITION OF S6 KINASE SUPPRESSES THE APOPTOTIC EFFECT OF EIF4E
ABLATION BY INDUCING TGF-β-DEPENDENT G1 CELL CYCLE ARREST
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4.1 ABLATION OF EIF4E EXPRESSION INDUCES APOPTOSIS IN THE PRESENCE
OF SERUM IN MDA-MB-231 CELLS
Previously, we reported that high (20 µM) rapamycin doses induced apoptosis in MDAMB-231 as well as in other cancer cell lines in the absence of serum [27, 58, 122, 123]. The
apoptotic effect was due to complete dephosphorylation of 4E-BP1,
inactivated eIF4E [130, 131].

which subsequently

The indirect effect of rapamycin on eIF4E correlated with

knockdown of eIF4E as this also induced apoptosis. In contrast, rapamycin induced cell cycle
arrest in the presence of serum [132]. It is not possible to evaluate the direct effect of inhibiting
eIF4E on cell cycle arrest by rapamycin treatment because the high dose required for arrest
inhibits both S6 kinases along with 4E-BP1. Thus, to investigate how the absence of eIF4E
affects cell cycle progression, we used siRNA against eIF4E in MDA-MB-231 cells.
Surprisingly, knockdown of eIF4E induced cell death in the presence and absence of serum
(Fig.15). The loss of cell viability was accompanied by cleavage of the caspase 3 substrate
PARP, indicating apoptotic cell death (Fig.15). Thus, whereas rapamycin induced apoptosis
only in the absence of serum [132], ablation of eIF4E induced apoptosis in both the presence and
absence of serum.
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Figure 15: Ablation of eIF4E expression induces apoptosis in the presence of serum in
MDA-MB-231 cells. MDA-MB-231 cells were transfected at 50% confluence with negative
control siRNA or siRNA for eIF4E. 24 hr later, the cells were put in fresh media with either 0%
or 10% serum. After another 24, the percentage of non-viable cells was determined as described
in Materials and Methods. Also at determined at this time was the level of cleaved PARP,
eIF4E, and actin by Western blot analysis. The cell viability data is representative of data
obtained from at least four independent experiments. The immunoblots are representative of
experiments repeated at least two times.

4.2. SUPPRESSION OF S6 KINASE PREVENTS THE APOPTOTIC EFFECT OF
SUPPRESSED EIF4E EXPRESSION IN THE PRESENCE OF SERUM
Since high-dose rapamycin treatment also inhibits S6 kinase phosphorylation, we reasoned
that protection from apoptosis induced by high-dose rapamycin in serum could be due to
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suppression of S6 kinase. Therefore, we investigated the effect of low-dose rapamycin treatment
upon eIF4E knockdown in MDA-MB-231 cells. Low-dose rapamycin treatment (20 nM)
prevented the apoptotic cell death induced by singular inhibition of eIF4E expression in the
presence, but not in the absence of serum (Fig. 16A). Thus, doses of rapamycin that suppress S6
kinase phosphorylation, but not 4E-BP1 phosphorylation [132], provided the cells with a means
of resistance to eIF4E ablation in the presence of serum.
We also investigated the effect of dual knockdown of S6 kinase and eIF4E. As with lowdose rapamycin treatment, suppression of S6 kinase expression prevented the apoptotic effect of
eIF4E ablation only in the presence of serum (Fig. 16B). Taken together, these data demonstrate
that suppression of either S6 kinase phosphorylation or the expression of S6 kinase prevented the
apoptotic effect of singularly suppressing eIF4E expression in the presence, but not in the
absence, of serum.
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Figure 16: Suppression of S6 kinase reverses the apoptotic effect of suppressed eIF4E
expression. (A) MDA-MB-231 cells were transfected at 50% confluence with negative control
siRNA or siRNA for eIF4E as indicated. 24 hr later, the cells were put in fresh media containing
either 10% or 0% serum and the indicated concentration of rapamycin or DMSO vehicle. After
another 24 hr, the level of cleaved PARP, eIF4E, P-S6 kinase, and S6 kinase by Western blot
analysis. (B) MDA-MB-231 cells were transfected at with negative control siRNA, siRNA for
eIF4E, or S6 kinase as indicated. 24 hr later, the cells were put in fresh media with 10% serum.
After another 24 hr, the level of cleaved PARP, eIF4E, S6 kinase, and actin by Western blot
analysis. The data are representative of experiments repeated at least two times.
4.3. SUPPRESSION OF APOPTOSIS BY S6 KINASE ABLATION IS DEPENDENT ON
TGF-β SIGNALING
We previously reported that the protective effect of serum upon rapamycin treatment was
contingent upon the TGF-β signaling, which induced a G1 cell cycle arrest [27, 132]. Therefore,
we examined whether prevention of apoptosis by dual inhibition of S6 kinase and eIF4E was
dependent on TGF-β signaling. MDA-MB-231 cells were co-treated with siRNAs against eIF4E
and S6 kinase and either a neutralizing anti-TGF-β antibody, rottlerin – a compound that inhibits
protein kinase Cδ (PKCδ) [27], which is required for TGF-β signaling [127, 128], or siRNA
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against Smad4, which is also required for canonical TGF-β signaling [133]. All three cotreatments resulted in induction of cleaved PARP (Fig. 17A). Similarly, we also asked if the
protective effect of low-dose rapamycin treatment upon eIF4E ablation was dependent on TGFβ. In fact, rottlerin treatment prevented the protective effect of low-dose rapamycin (Fig. 17B).
We also examined the effect of suppressing eIF4E and S6 kinase in BT-549 breast cancer cells
because they do not express PKCδ [134]. The BT549 cells remained sensitive to eIF4E ablation
upon S6 kinase knockdown (Fig. 17C). These data demonstrate that the S6 kinase suppression
of the apoptotic effect of eIF4E ablation is dependent on TGF-β signals.
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Figure 17: Suppression of apoptosis by S6 kinase ablation is dependent on TGF-β
signaling. (A) MDA-MB-231 cells were transfected at 50% confluence with negative control
siRNA, siRNA for eIF4E, S6 kinase, or Smad4 as indicated. 24 hr later, the cells were put in
fresh media with 10% serum and a neutralizing TGF-β antibody or rottlerin (Rott) (3 µM) where
indicated. After another 18 hr, the level of cleaved PARP, eIF4E, S6 kinase, Smad4, and actin
by Western blot analysis. (B) MDA-MB-231 cells were transfected with negative control siRNA
or siRNA for eIF4E as in (A). 24 hr later, the cells were put in fresh media with 10% serum and
either 20 nM rapamycin or DMSO vehicle where indicated. Where indicated, rottlerin (Rott) (3
µM) was also provided. After another 18 hr, the level of cleaved PARP, eIF4E, and S6 kinase
by Western blot analysis. (C) BT-549 cells were prepared and transfected with negative control
siRNA, siRNA for eIF4E, or S6 kinase as indicated. 24 hr later, the cells were put in fresh media
with 10% serum and rapamycin (20 nM) where indicated. After another 18 hr, the level of
cleaved PARP, eIF4E, and S6 kinase by Western blot analysis. The data are representative of
experiments repeated at least two times.

4.4. SUPPRESSION OF S6 KINASE INDUCES G1 ARREST IN CELLS WITH
ABLATED EIF4E.
While low-dose rapamycin induced TGF-β signaling,[32] it only weakly suppressed G1
cell cycle progression in MDA-MB-231 cells [120, 132]. High-dose (20 µM) was required to
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completely block synchronized cells from entering S-phase [132]. Therefore, we compared the
effect of low- dose rapamycin and suppression of S6 kinase expression on MDA-MB-231 cells
with ablated eIF4E expression on cell cycle progression. Both low-dose rapamycin (Fig. 18A)
treatment and suppression of S6 kinase expression (Fig. 18B) resulted in the accumulation of
cells with G1 DNA content and corresponding reductions in the number of cells with S-phase
DNA content. These data demonstrate that the TGF-β-dependent suppression of G1 cell cycle
progression in the presence of serum results in G1 cell cycle arrest – consistent with the idea that
blocking cell cycle progression (from G1 into S-phase) prevents apoptosis associated with the
absence of eIF4E expression.
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Figure 18: Suppression of S6 kinase induces G1 arrest in cells with ablated eIF4E.
(A) MDA-MB-231 cells were transfected at 50% confluence with negative control siRNA or
siRNA for eIF4E. 24 hrs later, the cells were put in fresh media with 10% serum and the
indicated concentrations of rapamycin. (B) MDA-MB-231 cells were transfected at 50%
confluence with negative control siRNA, siRNA for eIF4E, or S6 kinase. 24 hrs later, the cells
were put in fresh media with 10% serum. The cells in both (A) and (B) were then subjected to
flow cytometric analysis 24 hrs. later as described in Materials and Methods. The DNA content
per cell shown graphically above is from a representative experiment that was repeated three
times.
4.5 DISCUSSION
Previously, we reported that rapamycin caused G1 cell cycle arrest in the presence of
serum [132]. We associated the effect of high-dose rapamycin on inhibition of 4E-BP1
phosphorylation with an indirect inhibition of eIF4E [132]. Here, we investigated the role of
eIF4E in cell cycle arrest. Surprisingly, we observed cell death upon eIF4E knockdown in
MDA-MB-231 breast cancer cells in both the presence and absence of serum. Since high-dose
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rapamycin treatment continues to suppress phosphorylation of S6 kinase (as it does at low
doses), we reasoned that cells avoid the apoptosis induced by high-dose rapamycin through
suppression of S6 kinase. In fact, the MDA-MB-231 cells were insensitive to eIF4E knockdown
with suppression of S6 kinase phosphorylation or its expression. Preventing apoptosis was due
to a de-repression of S6 kinase-dependent inhibition of TFG-β signaling in the presence of serum
that prevented G1 cell cycle progression.
Our findings have implications on the cytostatic and cytotoxic properties of rapamycin.
Administered at nano-molar doses, rapamycin has generally been considered a cytostatic drug
[135]. These concentrations suppress S6 kinase phosphorylation but actually only retard G1 cell
cycle progression [13, 132]. Instead, micro-molar doses of rapamycin that also suppress the
phosphorylation of 4E-BP1 are required to achieve complete G1 cell cycle arrest [132]. Cell
cycle arrest observed with high-dose rapamycin treatment in the presence of serum is contingent
upon TGF-β signaling, which is suppressed by active mTORC1 [31, 32, 116]. Cancer cells with
defective TGF-β, in principle, should undergo apoptosis rather than arrest upon high-dose
rapamycin treatment. Defective TGF-β signaling is common in both pancreatic [136] and colon
cancer [137, 138]. Thus, these cancers may be candidates for targeting the phosphorylation of
4E-BP1 by mTORC1.
With regard to targeting mTORC1, our study stresses the importance of evaluating S6
kinase, 4E-BP1 and eIF4E with mTORC1 inhibitors. Logically, the requirement to suppress 4EBP1 phosphorylation in order to achieve complete G1 arrest may be linked to an eIF4E-bound
state. Dephosphorylation of all 4E-BP1 sites in a hierarchical manner is necessary to release
eIF4E [139]. eIF4E initiates cap-dependent translation of mRNAs for the translation of mRNAs
of proteins involved in cell cycle progression [130, 131]. The lack of expression of proteins
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critical for progression through S-phase may explain why suppression of eIF4E is cytotoxic if
cell death is not preempted by an arrest in G1.
Another issue with regard to targeting 4E-BP1 phosphorylation with rapamycin, is that the
level needed to suppress all 4E-BP1 phosphorylation sites in cell culture exceeds the maximum
tolerated dose in the clinic [140, 141]. However, sustained rapamycin treatment has been shown
to suppress mTORC2 [142], which is even more resistant to rapamycin than the mTORC1
phosphorylation of 4E-BP1. The impact of rapamycin on 4E-BP1 phosphorylation has been
examined in clinical trials [141], however these trials examined the impact on the
phosphorylation of 4E-BP1 at Thr70, which is sensitive to doses of rapamycin that suppress S6
kinase phosphorylation [132]. The key sites where the phosphorylation correlates with the
cytotoxic effects are Thr37/46 and Ser65 [132]. It remains to be seen whether rapamycin can
suppress phosphorylation on these sites with prolonged rapamycin treatment.
Another problem associated with targeting mTORC1 with rapamycin is that inhibiting
mTORC1 and S6 kinase phosphorylation stimulates a feedback activation of the pro-survival
mTOR complex 2 (mTORC2) in many cancer cells [143, 144]. The initial solution was the
development of catalytic inhibitors that effectively target both mTOR complexes [145, 146].
However, the true efficacy in the catalytic inhibitors may not be its inhibition of mTORC2 but
rather the ability to suppress the phosphorylation of both S6 kinase and 4E-BP1. The toxicity of
the catalytic inhibitors has not yet been fully evaluated.
Another approach would be to uncouple the effect of rapamycin on S6 kinase and 4E-BP1
phosphorylation by inhibiting the effect of suppressed S6 kinase phosphorylation – namely TGFβ signals. This could be done with compounds that inhibit the TGF-β signals that promote G1
cell cycle arrest. Thus, while targeting 4E-BP1 phosphorylation and eIF4E-dependent protein
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synthesis, may present challenges, understanding the limits of rapamycin-based therapies
suggests novel approaches that can exploit the critical mTORC1 signaling node that promotes
cell cycle progression and survival in what may be virtually all human cancers.
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CHAPTER V:
RAPAMYCIN INDUCED G1 ARREST EMPLOYS TGF-Β AND RB PATHWAY
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5.1 LOW DOSE OF RAPAMYCIN AND SUPPRESSION OF S6 KINASE ELEVATE
TGF-Β SIGNALS
We previously reported that rapamycin caused a TGF-β-dependent G1 cell cycle arrest in
MDA-MB-231 [147]. We also demonstrated that while G1 cell cycle progression in MDA-MB231 breast cancer cells could be somewhat retarded by conventional nano-molar doses of
rapamycin, complete G1 arrest required micro-molar doses of rapamycin [122]. TGF-β signaling
is suppressed by mTORC1 and therefore is activated in response to rapamycin treatment [27,
129]. We therefore investigated the dose of rapamycin required to induce TGF-β signaling in
MDA-MB-231 cells. Following stimulation with TGF‑β, Smad2 and Smad3 become
phosphorylated at carboxyl terminal serine residues (Ser465 and 467 on Smad2; Ser423 and 425
on Smad3) by TGF‑β receptor I [148]. As shown in Fig.19A, the induction of both Smad2 and
Smad3 phosphorylation with rapamycin could be achieved between 20 and 200 nM in MDAMB-231 cells. This induction correlated with the loss of S6 kinase phosphorylation. We
therefore examined whether suppression of S6 kinase expression could elevate Smad
phosphorylation. MDA-MB-231 cells were treated with siRNA directed against S6 kinase and
the level of phosphorylated Smad3 was determined. As shown in Fig. 19B, suppressing S6
kinase expression, like rapamycin, elevated the level of phosphorylated Smad3. These data
demonstrate that suppression of S6 kinase phosphorylation is sufficient to elevate TGF-β
signaling and establish a correlation between the suppression of S6 kinase phosphorylation and
increased TGF-β signaling.
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Figure 19: Low dose of rapamycin and suppression of S6 kinase causes Smad
phosphorylation. (A) MDA-MB-231 cells were plated at a density of 400,000/60 mm dish in
complete medium containing 10% serum overnight. Cells were treated with rapamycin for 24
hrs. at the indicated doses. Cells were then harvested and the levels of P-Smad2S465/467, Smad2,
and P-Smad3S423/425, Smad3, P-S6 kinaseT389 and S6 kinase were determined by Western blot
analysis. (B) MDA-MB-231 cells were plated at a density of 300,000 in a 6 well plate in media
containing 10% serum and no antibiotics overnight. Cells were transfected with negative control
siRNA or siRNA for S6 kinase as indicated. Six hrs later the cells were shifted to regular media.
24 hrs after transfection, cells were treated with rapamycin (200 nM) where indicated. After
another 24hr, the level of P-Smad3, Smad3, P-S6 kinase, S6 kinase and actin were determined by
Western blot analysis. All data are representative of at least two independent experiments.
5.2 HIGH DOSE RAPAMYCIN INHIBITS RB PHOSPHORYLATION AND
SUPPRESSES CYCLIN D1 EXPRESSION
While suppression of S6 kinase phosphorylation is apparently sufficient to de-repress
TGF-β signaling, the low dose rapamycin treatments capable of suppressing S6 kinase
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phosphorylation are not sufficient to induce complete G1 cell cycle arrest in MDA-MB-231 cells
[122]. TGF-β suppresses G1 cell cycle progression by elevating the levels of p21 and p27 –
factors that suppresses cyclin E/cyclin-dependent kinase (CDK) [133, 149]. Rapamycin causes a
late G1 cell cycle arrest that occurs at a point in G1 that depends upon the phosphorylation of Rb
by cyclin D-CDK4/6 and cyclin E-CDK2 [8, 150]. Since Rb phosphorylation is critical for late
G1 cell cycle progression, we examined the effect of rapamycin on Rb phosphorylation. As
shown in Fig. 20A, rapamycin inhibited Rb phosphorylation in MDA-MB-231. Importantly, the
effect required the micro-molar doses needed to suppress 4E-BP1 phosphorylation (Fig. 20B)
[122] The effect of rapamycin on 4E-BP1 phosphorylation was examined at 4 hrs. in Fig. 20B as
opposed to the 24 hrs time point used in Fig. 20A. This was due to a stronger effect of
rapamycin at the 4 hrs. time point for suppression of 4E-BP1, which becomes re-phosphorylated
at the 24 time point an effect that has been we and others have observed previously [121, 150]
These data reveal a correlation between suppression of Rb phosphorylation and the complete G1
cell cycle arrest induced by micro-molar doses of rapamycin.
To further that the effect of rapamycin is due to inhibition of 4E-BP1 phosphorylation, we
used a siRNA knockdown approach. The phosphorylation of 4E-BP1 by mTORC1 results in the
liberation of eIF4E, which can then facilitate cap-dependent translation of RNAs that encode
proteins critical for cell cycle progression [151]. We demonstrated previously that suppressing
expression of both S6 kinase and eIF4E resulted in G1 cell cycle arrest [147]. To determine
whether the phosphorylation of Rb stimulated by high dose rapamycin was dependent on the
inhibition of 4E-BP1 phosphorylation, we investigated whether suppressing eIF4E expression
would suppress Rb phosphorylation. As shown in Fig. 20C, suppressing eIF4E expression with
siRNA suppressed the phosphorylation Rb in MDA-MB-231 cells. Suppression of S6 kinase
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expression did not significantly affect Rb phosphorylation. These data indicate that the
suppression of Rb phosphorylation by high dose rapamycin is due to inhibition of 4E-BP1
phosphorylation and the consequent sequestration of eIF4E.
Proud and colleagues [149] reported previously that regulation of cyclin D1 expression by
mTOR was mediated at the translational level and required eIF4E as evidenced by the loss of an
effect of rapamycin when 4E-BP1 expression was suppressed. We therefore looked at the dose
response to rapamycin of cyclin D1 expression. As shown in Fig. 20D, rapamycin suppressed
cyclin D1 expression at micro-molar doses. These data further support the hypothesis that the
high dose rapamycin requirement for complete G1 arrest involves the suppression of 4E-BP1
phosphorylation and the subsequent phosphorylation of Rb.
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Figure 20: High dose rapamycin inhibits Rb phosphorylation and suppresses cyclin D1
expression. (A) MDA-MB-231 cells were plated as in Fig. 1A. Cells were then treated with
rapamycin for 24 hr at the indicated doses. Cells were then harvested and the levels of PRbS780, Rb, P-Smad3, Smad3, P-S6 kinaseT389 and S6 kinase were determined by Western
blot analysis. (B) MDA-MB-231 cells were plated as in Fig. 1A. Cells were then treated with
rapamycin with the indicated doses for 4hr and the levels of P-4E-BP1T37/46 and total 4E-BP1
was determined by Western blot analysis. (C) MDA-MB-231 cells were plated as in Fig. 1B.
Cells were transfected with negative control siRNA, siRNA for eIF4E or S6 kinase as indicated.
6 hrs later the cells were shifted to regular media. 48 hrs later, the level of P-Rb, Rb, eIF4E, S6
kinase and actin was determined by Western blot analysis. (D) MDA-MB-231 cells were plated
as in Fig. 1A. Cells were treated with rapamycin for 24 hrs at indicated doses. Cells were then
harvested and the levels of cyclin D1 and actin were determined by Western blot analysis. All
data are representative of at least two independent experiments.

5.3 MCF7 BREAST CANCER CELLS DISPLAY A GREATER SENSITIVITY TO
RAPAMYCIN
The data in Figs. 19 and 20 reveal that different doses of rapamycin that suppress TGF-β
signals are at least an order of magnitude less than that needed to suppress Rb phosphorylation
and cyclin D1. This reflects the differential sensitivity of mTORC1 to rapamycin for different
substrates – with S6 kinase phosphorylation being sensitive to low nano-molar concentrations,
and 4E-BP1 needing micro-molar concentrations to suppress phosphorylation [122]. We
demonstrated previously that the difference was due to partial, as opposed to complete,
dissociation of mTOR from the substrate-recognizing mTORC1 subunit Raptor [122]. Another
critical factor relating to rapamycin dose is that in different cancer cell lines, different doses of
rapamycin are required to suppress phosphorylation of the same substrate. We previously
reported that while suppression of S6 kinase phosphorylation in MDA-MB-231 required around
50 nano-molar rapamycin, whereas in MCF7 breast cancer cells, S6 kinase phosphorylation
could be suppressed at 1 nano-molar 4. This was due to elevated levels of phospholipase D
activity in MDA-MB-231 cells [58]. Phospholipase D generates the metabolite phosphatidic
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acid, which interacts with and activates mTOR in a manner that is competitive with rapamycin
[61]. We therefore investigated the effect of rapamycin on the parameters that control cell cycle
progression in response to rapamycin in MCF7 cells. As shown in Fig. 21A, it can be seen that
the levels of rapamycin needed to suppress Smad2 and Smad3 phosphorylation were somewhat
less than that needed to suppress the phosphorylation of Smad2 and Smad3 in MDA-MB-231
cells (Fig. 19 and 20). More significantly, Rb phosphorylation and cyclin D1 expression in
MCF7 cells (Fig. 21A) were sensitive to substantially lower doses of rapamycin than that needed
in MDA-MB-231 cells (Fig. 20A). As with MDA-MB-231 cells long-term rapamycin treatment
was less effective at suppressing 4E-BP1 than was a 4-hr treatment. However, as shown,
rapamycin could suppress 4E-BP1 phosphorylation at the same dose that suppressed Rb
phosphorylation and cyclin D1 expression (Figs. 21A and 21B). Thus, while MCF7 cells are
more sensitive to rapamycin than MDA-MB-231 cells, they also display the differential
sensitivity to rapamycin for TGF-β signaling and Rb phosphorylation.
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Figure 21: MCF-7 cells display greater sensitivity to rapamycin. (A) MCF-7 cells were
plated as in Fig. 1A. Cells were then treated with rapamycin for 24 hrs at indicated doses. Cells
were then harvested and the levels of P-Smad2, Smad2, P-Smad3, Smad3, P-S6 kinase, S6
kinase, P-Rb, Rb and cyclin D1 were determined by Western blot analysis. All data are
representative of at least two independent experiments. (B) MCF-7 cells were plated as in Fig.
1A. Cells were then treated with rapamycin with the indicated doses for 4hr and the levels of P4EBP1T37/46 and total 4EBP1 was determined by Western blot analysis.
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5.4 HIGH DOSE RAPAMYCIN EMPLOYS BOTH TGF-β AND RB TO CAUSE G1
ARREST
To further establish that the G1 cell cycle arrest caused by high dose rapamycin was due to
inhibition of both S6 kinase and 4E-BP1 phosphorylation, we examined the effect of high dose
rapamycin on cell cycle progression in MDA-MB-231 cells where we suppressed TGF-β
signaling along with suppression of Rb expression. As shown in Fig. 22B and C, high dose
rapamycin increased the percentage of cells in G1 as reported previously [122, 147]. Upon
phosphorylation, Smad2 or Smad3 combines with Smad4 and migrates to the nucleus where it
acts as a transcription factor [133]. We therefore suppressed the expression Smad4 along with
Rb using siRNAs. As shown in Fig. 22B, suppression of both Smad4 and Rb expression did not
significantly alter the percentage of cells in G1; however, under these conditions, rapamycin was
no longer able to increase the percentage of cells in G1. The same results were obtained using
SB-431542 (Fig. 22C), a compound that inhibits the TGF-β receptor [126]. These data
demonstrate that the ability of high dose rapamycin to arrest MDA-MB-231 cells in G1 is
dependent on both TGF-β and Rb.
We reported previously that in the absence of TGF-β, high dose rapamycin treatment
results in apoptotic cell death in MDA-MB-231 cells [27, 122, 147, 152]. As expected,
rapamycin induced cleavage of the caspase 3 substrate poly-ADP ribose polymerase (PARP) in
MDA-MB-231 cells that had been treated with siRNA for the co-Smad - Smad4. However, as
shown in Fig. 22A, the loss of both TGF-β signals and Rb did not result in apoptosis as indicated
by the lack of PARP cleavage, which was observed with the combination rapamycin and
suppression of Smad4 expression. Apparently, the loss of Rb and the concomitant release of
E2F family transcription factors prevented the apoptosis observed with rapamycin treatment in
cells with defective TGF-β signalin
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Figure 22: Rapamycin employs TGF-β and Rb pathway to cause cell cycle arrest. (A)
MDA-MB-231 cells were plated as in Fig. 1B. The cells were transfected with scrambled
(Scram) siRNA, siRNA for Rb or Smad4 as indicated. 6hrs later, the cells were shifted to a 10
cm dish containing regular media. 24 hrs after transfection rapamycin (20µM) was added where
indicated. After an additional 48hrs the cells were collected for flow cytometry and Western blot
analysis. (B) MDA-MB-231 cells were plated as in Fig. 1B. The cells were transfected with
scrambled siRNA or siRNA for Rb where indicated. 6hrs later, the cells were shifted to 10 cm
dish containing regular media. 24 hrs after transfection rapamycin (20µM) or SB-431542 (SB)
(10µM) was added where indicated. After an additional 48hrs the cells were collected for FACS
and Western blot analysis. The DNA content per cell shown graphically in (A) and (B) is from a
representative experiment that was repeated at least twice. (C) MDA-MB-231 cells were plated
as in Fig. 1B. Cells were transfected with negative control siRNA, siRNA for Smad4 or Rb as
indicated. 6 hrs later the cells were shifted to fresh regular media. 24 hrs after transfection, cells
were treated with rapamycin (20µM) where indicated. After another 18hr, the levels of cleaved
PARP (Cl PARP), Smad4, Rb and actin were determined by Western blot analysis. The data are
representative of experiments repeated at least two times.

5.5 DISCUSSION
In this report, we have identified a missing factor in rapamycin-induced TGF-β-dependent
G1 cell cycle arrest. We previously reported that complete G1 cell cycle arrest in MDA-MB-231
cells required high micro-molar doses of rapamycin, whereas low nano-molar doses are
sufficient for activating TGF-β signals. Rapamycin suppresses S6 kinase phosphorylation at
nano-molar doses, however micro-molar doses are required for suppression of 4E-BP1
phosphorylation. In this report, we have provided evidence that complete G1 cell cycle arrest
requires suppression of both S6 kinase-dependent inhibition of TGF-β signals and 4E-BP1dependent suppression of Rb phosphorylation.
The integration of TGF-β signals with Rb highlights the significance of cyclin E-CDK2,
which phosphorylates Rb in late G1 to promote cell cycle progression into S-phase [153]. Rb
becomes hyper-phosphorylated by cyclin E/CDK2 and dissociates from E2F family transcription

62	
  
	
  

factors allowing E2F to stimulate the expression of genes critical for progression from G1 into Sphase [20, 154]. TGF-β stimulates the expression of the cyclin E-CDK2 inhibitors p21Cip1 and
p27Kip1 [155]. Thus, in principle, elevating TGF-β could suppress Rb phosphorylation.
However, as shown in Fig. 20, nano-molar doses of rapamycin could completely suppress S6
kinase phosphorylation, but only partially inhibited Rb phosphorylation. This consistent with a
previous report by Blenis and colleagues where nano-molar doses of rapamycin slowed G1
progression, but did not arrest cells in G1[13]. The high doses of rapamycin that completely
block G1 cell cycle progression [122, 150] caused a more significant drop in Rb phosphorylation
that was dependent on suppression of 4E-BP1 phosphorylation, which results in the sequestration
of eIF4E. Thus, while de-repression of TGF-β signaling by low dose rapamycin is necessary for
blocking G1 cell cycle progression, suppression of eIF4E, which requires higher doses of
rapamycin, is also required. These data indicate a more complex regulation of the cyclin ECDK2 cell cycle checkpoint that involve signal input to both TGF-β signals and Rb involve
cyclin D-CDK4/6 and cyclin E-CDK2. This is shown schematically in Fig. 23.
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Figure 23: Model for the differential effects of low and high dose rapamycin. Low dose
rapamycin inhibits S6 kinase and thereby up regulates TGF-β signaling. Up regulation of TGF-β
signaling is insufficient to cause cell cycle arrest. High dose rapamycin inhibits S6 kinase and
eIF4E and thus activates TGF-β signaling and Rb, both of which are required for causing cell
cycle arrest.
While it is not clear how eIF4E contributes to the suppression of Rb phosphorylation, it
was reported that a constitutively active 4EBP-1, which suppresses eIF4E, caused a cell cycle
arrest in MCF7 cells that correlated with decreased cyclin E-CDK2 activity and increased
association of CDK2 with p27Kip1 [156]. It was also reported that rapamycin can suppress cyclin
D levels in a manner that could be reversed with suppression of 4E-BP1 – indicating that the
effects of rapamycin were mediated by suppression of 4E-BP1 phosphorylation [149]. While the
concentrations of rapamycin used (100 nM) are not sufficient to suppress 4E-BP1
phosphorylation in most cells [122], the effect was only observed in MCF7 cells, which are
much more sensitive to rapamycin than most cell lines [58]. However, if mTORC1 was
suppressed by amino acid withdrawal, which inhibited 4E-BP1 phosphorylation, then cyclin D
levels were reduced in HEK-293 cells that were resistant to 100 nM rapamycin [149]. Data
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provided here (Figs. 2 and 3) show that cyclin D levels and Rb phosphorylation were sensitive to
nano-molar levels of rapamycin in MCF7 cells (Fig. 21) and micro-molar levels in MDA-MB231 cells (Fig. 20).
Since cyclin D-CDK4/6 mono-phosphorylates Rb, which is required for the
phosphorylation of Rb by cyclin E/CDK2 [157], suppression of cyclin D levels would also
suppress the ability of cyclin E/CDK2 to phosphorylate Rb. In that cyclin D-CDK4/6 complexes
bind p27 and prevent it from binding to cyclin E-CDK2 where it is inhibitory [157], reduced
cyclin D levels could lead to elevated levels of p27 that could also contribute to the suppression
of cyclin E/CDK2 activity. We demonstrated here that cyclin D1 levels were suppressed by
doses of rapamycin needed to suppress 4E-BP1 phosphorylation. Thus, it is likely that the key
effect of high dose rapamycin treatment on G1 cell cycle progression was to prevent eIF4Edependent translation of cyclin D1. Consistent with this hypothesis, it was reported that
rapamycin inhibited cyclin D1 expression at the level of translation [149, 158].
An intriguing finding here was that suppressing both TGF-β signaling and Rb expression
did not result in cell death with high dose rapamycin treatment – as was observed with
suppression of TGF-β signaling alone [116]. This finding suggests that rapamycin-induced
suppression of Rb phosphorylation – and the sequestration of E2F family transcription factors –
is responsible for the cell death observed with the high dose rapamycin treatment that inhibits
4E-BP1 phosphorylation. The data are consistent with a model whereby the lack of TGF-β
signals allows cells to progress into S-phase, but with suppression of Rb phosphorylation,
expression of E2F is suppressed and the genes needed for S-phase are not expressed. Since the
cell cycle is not reversible at this point, the cells undergo apoptosis. Thus, Rb-null cancer cells
are not likely to be vulnerable to therapeutic strategies that target mTOR.
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CHAPTER VI
CONCLUSIONS AND FUTURE DIRECTIONS
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6.1 CONCLUSION
Previously, our lab has reported that rapamycin caused G1 cell cycle arrest in the presence
of serum [132]. We associated the effect of high-dose rapamycin on inhibition of 4E-BP1
phosphorylation with an indirect inhibition of eIF4E [132]. Here, we investigated the role of
eIF4E in cell cycle arrest. Surprisingly, we observed cell death upon eIF4E knockdown in
MDA-MB-231 breast cancer cells in both the presence and absence of serum. Since high-dose
rapamycin treatment continues to suppress phosphorylation of S6 kinase (as it does at low
doses), we reasoned that cells avoid the apoptosis induced by high-dose rapamycin through
suppression of S6 kinase. In fact, the MDA-MB-231 cells were insensitive to eIF4E knockdown
with suppression of S6 kinase phosphorylation or its expression. Preventing apoptosis was due
to a de-repression of S6 kinase-dependent inhibition of TFG-β signaling in the presence of serum
that prevented G1 cell cycle progression.
In this study, we have also identified a missing factor in rapamycin-induced TGF-βdependent G1 cell cycle arrest. Our lab has previously reported that complete G1 cell cycle
arrest in MDA-MB-231 cells required high micro-molar doses of rapamycin [122], whereas low
nano-molar doses are sufficient for activating TGF-β signals [27]. Rapamycin suppresses S6
kinase phosphorylation at nano-molar doses, however micro-molar doses are required for
suppression of 4E-BP1 phosphorylation. In this study, we have provided evidence that complete
G1 cell cycle arrest requires suppression of both S6 kiase-dependent inhibition of TGF-β signals
and 4E-BP1-dependent suppression of Rb phosphorylation.
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6.2 FUTURE DIRECTIONS
This study has shown the importance of Rb in rapamycin induced antiproliferrative effects.
Prior studies by Gadir et al have shown that rapamycin causes apoptosis in absence of TGF-β
signaling [27]. Following that we have shown that rapamycin fails to cause apoptosis in absence
of TGF-β signaling and Rb. It means that inhibition of Rb is preventing rapamycin induced
apoptosis on TGF-β inhibition. It would be interesting to find out what happens in Rb null cell
lines upon TGF-β inhibition and rapamycin addition. We can expect rapamycin will not cause
apoptosis which means rapamycin employs Rb to cause apoptosis. Overexpression of Rb in these
Rb null cell lines should rescue the phenotype and cause rapamycin induced cell death. Using
cell lines which are both TGF-β and Rb defective like DU-145 should as well fail to cause
rapamycin mediated apoptosis. Thus, this work can further shed light to the importance of Rb in
the anti proliferative role of rapamycin.
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